BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33045568)

  • 1. Integrative analysis of genomic alteration, immune cells infiltration and prognosis of lung squamous cell carcinoma (LUSC) to identify smoking-related biomarkers.
    Li J; Li H; Zhang C; Zhang C; Wang H
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107053. PubMed ID: 33045568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi-omics data.
    Yang S; Liu T; Liang G
    Mol Oncol; 2020 Sep; 14(9):2069-2080. PubMed ID: 32580248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
    Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
    Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative Analysis of Pyroptosis-Related Prognostic Signature and Immunological Infiltration in Lung Squamous Cell Carcinoma.
    Luo P; Jiang Y; Ding S; Jiang S; Tang R; Tang Z
    Biomed Res Int; 2022; 2022():4944758. PubMed ID: 35692583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of downregulated ADARB1 in lung squamous cell carcinoma.
    Wang X; Ren X; Liu W; Chen X; Wei J; Gong Z; Yan Y; Xu Z
    Mol Med Rep; 2020 Mar; 21(3):1517-1526. PubMed ID: 32016472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders.
    Liu B; Liu Y; Zou J; Zou M; Cheng Z
    Anticancer Agents Med Chem; 2022; 22(8):1541-1550. PubMed ID: 34315392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.
    Desrichard A; Kuo F; Chowell D; Lee KW; Riaz N; Wong RJ; Chan TA; Morris LGT
    J Natl Cancer Inst; 2018 Dec; 110(12):1386-1392. PubMed ID: 29659925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma.
    Xu Y; She Y; Li Y; Li H; Jia Z; Jiang G; Liang L; Duan L
    Biomed Pharmacother; 2020 May; 125():109859. PubMed ID: 32036209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network.
    Li R; Yang YE; Jin J; Zhang MY; Liu X; Liu XX; Yin YH; Qu YQ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3246-3258. PubMed ID: 31364871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma.
    Liu Z; Wan Y; Qiu Y; Qi X; Yang M; Huang J; Zhang Q
    Int J Med Sci; 2020; 17(10):1393-1405. PubMed ID: 32624696
    [No Abstract]   [Full Text] [Related]  

  • 13. [Exploring the Role of PCDHGB4 in the Occurrence of Lung Squamous Cell Carcinoma Based on Bioinformatics Analysis].
    Lu R; Abuduhailili X; Li Y; Ning J; Feng Y
    Zhongguo Fei Ai Za Zhi; 2024 Mar; 27(3):199-215. PubMed ID: 38590195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients.
    Zhang T; Yang H; Sun B; Yao F
    Aging (Albany NY); 2021 Jan; 13(3):3819-3842. PubMed ID: 33428598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune cell landscape analysis reveals prognostic immune cells and its potential mechanism in squamous cell lung carcinoma.
    Wang Y; Guo J
    PeerJ; 2020; 8():e9996. PubMed ID: 33083119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes.
    Deng X; Wang Z; Luo Y; Li Z; Chen L
    Medicine (Baltimore); 2022 Sep; 101(37):e30304. PubMed ID: 36123889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of DNA methylation-driven genes for the prognosis of lung squamous cell carcinoma using MethylMix.
    Li R; Yin YH; Jin J; Liu X; Zhang MY; Yang YE; Qu YQ
    Int J Med Sci; 2020; 17(6):773-786. PubMed ID: 32218699
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a Clinical Prognostic Model for Metabolism-Related Genes in Squamous Lung Cancer and Correlation Analysis of Immune Microenvironment.
    Zhuang Z; Gao C
    Biomed Res Int; 2022; 2022():6962056. PubMed ID: 36110123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
    Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
    Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.
    Zhang R; Zhang TT; Zhai GQ; Guo XY; Qin Y; Gan TQ; Zhang Y; Chen G; Mo WJ; Feng ZB
    World J Surg Oncol; 2018 Jun; 16(1):109. PubMed ID: 29914539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.